Pyoderma gangrenosum: Challenges and solutions

Clinical, Cosmetic and Investigational Dermatology

Volumn 8, Issue , 2015, Pages 285-293

  Gameiro, Ana ^a   Pereira, Neide ^b   Cardoso, José Carlos ^a   Gonçalo, Margarida ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b Dermatology Department Centro Hospitalar   (Portugal)

Author keywords

Biologics; Neutrophilic dermatosis; Pyoderma gangrenosum; Treatment

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CYCLOSPORIN; DAPSONE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MINOCYCLINE; NICOTINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STROMELYSIN 2; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLOOD CELL COUNT; BROMODERMA; CHRONIC VEIN INSUFFICIENCY; CLINICAL FEATURE; COLONOSCOPY; COMPRESSION THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FACTITIOUS DISEASE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INSECT BITE; LIVER FUNCTION TEST; MYCOSIS; NECROBIOSIS LIPOIDICA; PARASITOSIS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN EXPRESSION; PYODERMA GANGRENOSUM; QUALITY OF LIFE; REVIEW; SKIN BIOPSY; SKIN LYMPHOMA; SKIN TUMOR; SYMPTOMATOLOGY; TREATMENT OUTCOME; VASCULITIS;

EID: 84930628266     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/CCID.S61202     Document Type: Review

References (59)

1. Farhi D. The clinical and histopathological description of geometric phagedenism (pyoderma gangrenosum) by Louis Brocq one century ago. Arch Dermatol. 2008;144(6):755.
2. Gold S. Pyoderma Gangrenosum. Proc R Soc Med. 1956;49(4): 234–235.
3. Muende I. Pyoderma Gangrenosum. Proc R Soc Med. 1960;53(4): 296–297.
4. Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.
5. Wollina U. Pyoderma gangrenosum – a review. Orphanet J Rare Dis. 2007;2:19.
6. Wines N, Wines M, Ryman W. Understanding pyoderma gangrenosum: a review. MedGenMed. 2001;3(3):6.
7. Hemp L, Hall S. Pyoderma gangrenosum: from misdiagnosis to recognition, a personal perspective. J Wound Care. 2009;18(12):521–526.
8. Alavi A, Sajic D, Cerci FB, Ghazarian D, Rosenbach M, Jorizzo J. Neutrophilic dermatoses: an update. Am J Clin Dermatol. 2014;15(5): 413–423.
9. Cardoso JC, Coelho S, Gonçalo M, Oliveira H, Brites MM, Figueiredo A. Pioderma gangrenoso da parede abdominal após cesariana [Pyoderma gangrenosum of the abdominal wall after cesarean]. Trab Soc Port Dermatol Venereol. 2008;66:245–250.
10. Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol. 2000;143(4):728–732.
11. Kluger N. Ustekinumab for pyoderma gangrenosum. Arch Dermatol. 2012;148(5):655.
12. Kabashima R, Sugita K, Sawada Y, Hino R, Nakamura M, Tokura Y. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol. 2011;25(4):485–488.
13. Marzano AV, Cugno M, Trevisan V, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162(1):100–107.
14. Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.
15. Keller M, Spanou Z, Schaerli P, et al. T Cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol. 2005;175(11): 7678–7686.
16. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–181.
17. Caproni M, Antiga E, Volpi W, et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Brit J Dermatol. Epub January 20, 2015.
18. Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203–1205.
19. Marzano AV, Cugno M, Trevisan V, et al. Inflammatory cells, cytokines and matrix metalloproteinases in amicrobial pustulosis of the folds and other neutrophilic dermatoses. Int J Immunopathol Pharmacol. 2011;24(2):451–460.
20. Duchatelet S, Miskinyte S, Join-Lambert O, et al. First Nicastrin mutation in PASH syndrome. Br J Dermatol. Epub January 20, 2015.
21. Defilippis EM, Feldman SR, Huang WW. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol. Epub October 28, 2014.
22. Bruzzese V. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy. J Clin Rheumatol. 2012;18(8):413–415.
23. Goodarzi H, Sivamani RK, Garcia MS, et al. Effective Strategies for the Management of Pyoderma Gangrenosum. Adv Wound Care (New Rochelle). 2012;1(5):194–199.
24. Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11(5):447–449.
25. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23(9):1008–1017.
26. Pereira N, Brites MM, Gonçalo M, Tellechea O, Figueiredo A. Pyoderma gangrenosum – a review of 24 cases observed over 10 years. Int J Dermatol. 2013;52(8):938–945.
27. Wu XR, Shen B. Diagnosis and management of parastomal pyoderma gangrenosum. Gastroenterol Rep (Oxf). 2013;1(1):1–8.
28. Nguyen TV, Cowen EW, Leslie KS. Autoinflammation: From monogenic syndromes to common skin diseases. J Am Acad Dermatol. 2013;68(5):834–853.
29. Tüzün Y, Maraşoğlu O. Pyoderma Gangrenosum. J Turk acad Dermatol. 2007;1(3):71301r.
30. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53(2):273–283.
31. Landis ET, Taheri A, Jorizzo JL. Gulliver’s sign: A recognizable transition from inflammatory to healing stages of pyoderma gangrenosum. J Dermatolog Treat. In press 2014.
32. Von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137(6):1000–1005.
33. Patel F, Fitzmaurice S, Duong C, et al. Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review. Acta Derm Venereol. In press 2014.
34. Omiya W, Ujiie H, Akiyama M, et al. Coexistence of pustular and vegetative pyoderma gangrenosum in a patient with myelodysplastic syndrome. Eur J Dermatol. 2012;22(5):711–712.
35. Feliciani C, De Simone C, Amerio P. Dermatological signs during inflammatory bowel diseases. Eur Rev Med Pharmacol Sci. 2009;13 Suppl 1:15–21.
36. Speeckaert R, De Smet L, De Schepper S, et al. Pyoderma gangrenosum with granuloma formation: not always a benign disorder. J Eur Acad Dermatol Venereol. Epub August 29, 2014.
37. Dasanu CA, Bockorny B, Alexandrescu DT. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. J Oncol Pharm Pract. In press 2014.
38. Duchnowska R, Ziajka E, Góralska A, Grala B. Recurrent pyoderma gangrenosum precipitated by breast cancer: a case report and review of the literature. J Med Case Rep. 2014;8:226.
39. Doria A, Zen M, Bettio S, et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev. 2012;12(1):22–30.
40. Craig FF, Thomas KS, Mitchell EJ, et al. UK Dermatology Clinical Trials Network’s STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials. 2012;28;13:51.
41. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–509.
42. Sharon V, Burrall B, Patel F, et al. Multimodal therapy of idiopathic pyoderma gangrenosum. Dermatol Online J. 2014;15;20(6).
43. Andrade P, Brites MM, Figueiredo A. Synchronous pyoderma gangrenosum and inflammatory bowel disease, healing after total proctocolectomy. An Bras Dermatol. 2012;87(4):637–639.
44. Cosgarea I, Lovric Z, Körber A, Dissemond J. Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma. Int Wound J. Epub October 8, 2014.
45. Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol. 2012;7(4):271–275.
46. Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin. 2013;31(3):405–425.
47. Ye MJ, Ye JM. Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management. Dermatol Res Pract. Epub October 8, 2014.
48. DeMartyn LE, Faller NA, Miller L. Treating peristomal pyoderma gangrenosum with topical crushed prednisone: a report of three cases. Ostomy Wound Manage. 2014;60(6):50–54.
49. Kapila S, Reid I, Dixit S, et al. Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum. Clin Exp Dermatol. 2014;39(7):785–790.
50. Liu DY, Fischer R, Fraga G, Aires DJ. Collagenase ointment and topical timolol gel for treating idiopathic pyoderma gangrenosum. J Am Acad Dermatol. 2014;71(5):e225–e226.
51. Imus G, Golomb C, Wilkel C, Tsoukas M, Nowak M, Falanga V. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol. 2001;44(1):61–66.
52. Sick I, Trautner B, Ruzicka T. [Surgical management of Pyoderma gangrenosum]. Hautarzt. 2012;63(7):577–583. German.
53. Cafardi J, Sami N. Intravenous immunoglobulin as salvage therapy in refractory pyoderma gangrenosum: report of a case and review of the literature. Case Rep Dermatol. 2014;23;6(3):239–244.
54. Sinnya S, Hamza S. Pyoderma gangrenosum of the breast treated with intravenous immunoglobulin. J Dermatol Case Rep. 2013;30;7(2): 64–68.
55. Campanati A, Brisigotti V, Ganzetti G, et al. Finally, recurrent pyoderma gangrenosum treated with Adalimumab: case report and review of the literature. J Eur Acad Dermatol Venereol. In press 2014.
56. Cinotti E, Labeille B, Perrot JL, Pallot-Prades B, Cambazard F. Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis. Clin Exp Dermatol. 2014;39(6):750–751.
57. Staub J, Pfannschmidt N, Strohal R, et al. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol. In press 2014.
58. Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132(9):2166–2170.
59. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79(1):37–46.